AstraZeneca
Search documents
AstraZeneca(AZN) - 2020 Q4 - Annual Report
2021-02-16 11:08
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...
AstraZeneca(AZN) - 2020 Q4 - Earnings Call Transcript
2021-02-11 20:53
AstraZeneca PLC (NASDAQ:AZN) Q4 2020 Earnings Conference Call February 11, 2021 6:45 AM ET Company Participants Pascal Soriot - Executive Director and Chief Executive Officer Dave Fredrickson - Executive Vice President, Oncology Business Unit Ruud Dobber - Executive Vice President, Biopharmaceuticals Business Unit Marc Dunoyer - Executive Director and Chief Financial Officer Mene Pangalos - Executive Vice President, Biopharmaceuticals R&D Pam Cheng - Executive Vice President, Operations and IT Leon Wang - E ...
AstraZeneca(AZN) - 2020 Q3 - Earnings Call Transcript
2020-11-06 04:34
AstraZeneca PLC (NASDAQ:AZN) Q3 2020 Earnings Conference Call November 5, 2020 6:45 AM ET Company Participants Pascal Soriot – Chief Executive Officer Dave Fredrickson – Executive Vice President of the Oncology Business Unit Ruud Dobber – Executive Vice President of the Biopharmaceuticals Business Unit Marc Dunoyer – Executive Director and Chief Financial Officer Mene Pangalos – Executive Vice President of the Biopharmaceuticals R&D Group Jose Baselga – Executive Vice President of Oncology R&D Pam Cheng – E ...
AstraZeneca(AZN) - 2019 Q4 - Annual Report
2020-03-03 21:21
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) ...
AstraZeneca(AZN) - 2018 Q4 - Annual Report
2019-03-05 21:35
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) ...